NEW YORK – PerkinElmer has started targeting laboratories in different geographies with its Vanadis system for noninvasive prenatal cell-free DNA testing, following the publication of a European clinical validation study this summer. Earlier this month, the company also started accepting clinical samples at its laboratory in the US and an affiliate laboratory in Malaysia, allowing potential customers to familiarize themselves with the technology prior to making a purchase decision. In parallel, the company continues to collaborate with a US hospital on another clinical validation study.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.